[Retracted] Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4+CD25+FoxP3 Treg and CD4+IL17 T Cells
Figure 2
Flow cytometry analysis of the percentage of CD4+CD25+FoxP3 Treg and CD4+IL-17 T cells in PBMCs. (a), the percentage of CD4+CD25+FoxP3 Treg cells in the CG group before placebo intervention. (b), the percentage of CD4+IL-17 T cells in the CG group before placebo intervention. (c), the percentage of CD4+CD25+ FoxP3 Treg cells in the SG group before SSLK intervention. (d), the percentage of CD4+IL-17 T cells in the SG group before SSLK intervention. (e), the percentage of CD4+CD25+FoxP3 Treg cells in the CG group after 3-month placebo intervention. (b), the percentage of CD4+IL-17 T cells in the CG group after 3-month placebo intervention. (c), the percentage of CD4+CD25+ FoxP3 Treg cells in the SG group after 3-month SSLK intervention. (d), the percentage of CD4+IL-17 T cells in the SG group after 3-month SSLK intervention. In the SG group, the patients took SSLK and in the CG group, the patients took placebo.